Treatment planning study of cyberKnife prostate SBRT (stereotactic body radiation therapy) using CT-based vs MRI-based prostate volumes by Alotaibi, Abdulmajeed Modhi
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
Treatment planning study of
cyberKnife prostate SBRT
(stereotactic body radiation
therapy) using CT-based vs
MRI-based prostate volumes
https://hdl.handle.net/2144/16813
Boston University
		
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
TREATMENT PLANNING STUDY OF CYBERKNIFE PROSTATE SBRT  
 
(STEREOTACTIC BODY RADIATION THERAPY) USING 
 
CT-BASED VS. MRI-BASED PROSTATE VOLUMES 
 
 
 
by 
 
 
 
ABDULMAJEED MODHI ALOTAIBI 
 
B.Sc., Southern Illinois University, Carbondale, 2014 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science  
 
2016 
		
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 by 
ABDULMAJEED ALOTAIBI 
All rights reserved 
		
Approved by 
 
 
 
First Reader   
 Boris Nicolas Bloch, M.D. 
 Associate Professor of Radiology and Bioimaging Science 
  
 
 
Second Reader     
 Hong Xiang, Ph.D. 
 Assistant Professor of Radiation Oncology 
  
 
 
Third Reader   
 Kevin Thomas, Ph.D. 
 Assistant Professor of Bioimaging and Health Emergency 
   
 
 
 
		iv 
DEDICATION 
I would like to dedicate this work to my parents, and all my brothers and sisters 
who have been constantly supporting and motivating me during the challenge of 
graduate school and life. I am truly thankful to god for having them in life.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		v 
ACKNOWLEDGMENTS 
 
Words are powerless to express my gratitude to all those who have supported, 
inspired, and advised me especially:  
Dr. Boris Nicolas Bloch: I am greatly thankful to him for giving me the 
opportunity to work with the radiation oncology team under his supervision, and 
also for assisting me to pick my MRI thesis topic. Dr. Bloch has dedicated his 
time and knowledge to broaden my horizon in magnetic resonance imaging 
(MRI) and prostate cancer. He also helped me increasing the range of my clinical 
knowledge and experience and he has been always making sure that I am on the 
right track in terms of research work and he has never hesitated to correct me 
when I needed to be corrected. He is the one who has cultivated my research 
experience and made me that person who believes that the sky has no limits and 
he will not be forgotten. 
Dr. Hong Xiang: My heartfelt thanks go to Dr. Xiang for unselfishly giving me a 
part of his time mentoring me, improving my knowledge in the CyberKnifeTM of 
prostate SBRT, and eagerly reviewing my progress in MR/CT image fusion and 
radiation therapy treatment planning. He taught me how to use MIM and the 
CyberKnifeTM Multiplan software, which I used for this study. Dr. Xiang also has 
been reviewing my writing progress, and providing me with his thoughtful advice 
to accurately implement all research methods. He has been patiently working 
hard to assist his patients and students at the radiation oncology department. He 
will be always my role model and his help will never be forgotten.  
		vi 
Dr. Kevin Thomas: Special thanks go out to Dr. Thomas, and without his 
motivation and encouragement I would never have considered a graduate career 
in MRI research. He provided me with all insightful direction, support and became 
more of a co-director and a friend, than a professor. He also will never be 
forgotten.  
BMC Radiology and Radiation Oncology Staff: I also must acknowledge all 
clinicians at BMC radiology departments and the radiation oncology department, 
and I am grateful to them for helping me out and putting their trust into me since 
the first day I started working on my thesis research through to the completion of 
my degree.  
 
 
 
 
 
 
 
 
 
  
		vii 
TREATMENT PLANNING STUDY OF CYBERKINFE PROSTATE SBRT 
(STEREOTACTIC BODY RADIATION THERAPY) USING 
CT-BASED VS. MRI-BASED PROSTATE VOLUMES 
ABDULMAJEED MODHI ALOTAIBI 
 
ABSTRACT 
This study has been conducted for the purpose of investigating the systematic 
dose reduction of rectum and neurovascular bundles (NVBs) during treatment 
planning of the CyberKnifeTM prostate SBRT using CT-Based volumes versus 
MRI-based volumes. Three prostate cancer patients were planned for the 
CyberKnifeTM prostate SBRT and they underwent computed tomography (CT) 
and magnetic resonance imaging (MRI) preplanning exams. The patients were 
positioned during both exams using an immobilizing device. A radiation 
oncologist and a radiologist delineated the prostate gland, intra-prostatic and 
peri-prostatic structures, and pelvic organs of interest in both CT and MRI 
images. The CT and MRI images were fused based on fuducial markers to 
accurately align the prostate.  Radiation Therapy Oncology protocol RTOG 0938 
was followed to meet the target volume (prostate plus margin) dose coverage 
requirement, and dose-volume constraints for organs at risk, including rectum, 
bladder, femoral heads, penile bulb, urethra, skin and NVBs. Radiation dose 
volume parameters were recorded for both volumes and compared. The 
preliminary result shows that the CT-based volumes were generally larger than 
MRI-based volumes of the prostate. Therefore, the CT-based volumes resulted in 
		viii 
less accurate treatment planning and dose delivery to radiosensitive structures.   
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Chapter I: Introduction 
Prostate cancer has become a leading cause of death and the most commonly 
seen in men. In 2012, there was an estimated report for 2,795,592 men who 
have had prostate cancer in the United States. In 2015, the estimated number 
people with prostate cancer became 220,800 (Seer: Prostate Cancer). “In the 
United States, men currently have the risk of prostate cancer diagnosis is a 
17.3%, while the risk of prostate cancer death is 3% (Thompson, 2005).” 
Prostate cancer treatment decisions are based on the size of cancer and its 
aggressiveness. Some prostate cancers grow slowly and don’t need immediate 
treatment, and the patient may choose active surveillance. Other cancers, larger 
or more aggressive need surgical treatment or radiation treatment. Once the 
cancer is not gland confined, radiation therapy is the therapy of choice. Over the 
last decade, MRI has become the preferred imaging modality to detect and stage 
the prostate cancer, while CT is the standard tool to perform the treatment 
planning. For prostate cancer radiotherapy treatment, the CyberKnifeTM can be 
used in conjunction with Stereotactic Body Radiation Therapy (SBRT). SBRT is a 
new emerging technique, which delivers a single high radiation dose or multiple 
fractionated doses to the prostate gland. Also, the CyberKnifeTM SBRT of 
prostate cancer uses an X-ray beam accelerator equipped with a robotic arm, 
which allows tracking the prostate motion and delivering non-coplanar beams 
precisely. This study focuses on the systematic dose reduction to the rectum and 
neurovascular bundles in treatment planning of the CyberknifeTM prostate SBRT 
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using CT-based vs. MRI-based prostate volumes. 
 
Chapter II: Background 
2.1. Prostate Anatomy 
 
The prostatic gland is located in the male pelvic region, and it is about the size of 
a chestnut. The prostate gland is anatomically formed of an apex, a base, and 
four surfaces. It can be seen underneath the urinary bladder and in front of the 
rectum. The main function of the prostate is producing a thin protein fluid that 
also contains minerals. This prostatic fluid nourishes and transports sperms 
during orgasm. The prostate gland base is situated close to the inferior part of 
the urinary bladder, while the prostate gland apex is situated near the top surface 
of the urogenital diaphragm. The anterior prostatic lobe is known as the anterior 
part of the gland located in front of the urethra. The median prostatic lobe is 
about the shape of a cone, and it is the part of the gland located between the 
urethra and the ejaculatory ducts. The left and right prostatic lobes make the 
gland main part, and both lobes are divided by the prostatic urethra. The 
posterior prostatic lobe is located in the posterior and medial part of the prostate 
gland. (NCI Seer training, 2015) (See figures 1, 2 & 3). 
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Figure 1: Anatomy of the prostate gland (NCI, 2015). 
 
Figure 2: The prostate gland is highlighted in blue (MSD, 2012). 
 
Figure 3: The Prostate gland on three-plane MRI images (Kressel, 2014). 
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2.1.1 Prostate Zones and Function 
 
The prostate gland is separated into 3 zones: peripheral zone (PZ), transition 
zone (TZ), and central zone (CZ) (See figure 4 and 5). The peripheral zone is the 
biggest zone in the prostate that is located closest to the rectum and the doctor 
can easily feel it during a digital rectal examination (DRE). 75% of prostate 
tumors are found in the prostatic peripheral zone. The transitional zone is the 
area located in the middle of the prostate gland, between the two other zones. 
This zone surrounds the urethra and passes through the prostate and it builds up 
about 20% of the prostate gland until the age of 40. When men get older, the 
transitional zone starts to become larger, until it turns to be the largest area of the 
prostate. When the transitional zone enlarges, it starts pushing the peripheral 
zone of the prostate all the way towards the rectum. The central zone is in front 
of the transitional zone and it is the part of the prostate located far from the 
rectum (Canadian Cancer Society, 2016). 
 
Figure 4 & Figure 5 The three prostate zones (NCI, 2015) (Vilanova, 2012). 
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2.2 Prostate Cancer 
 
“Prostate cancer has the highest prevalence of any non-skin cancer in the human 
body, with similar likelihood of neoplastic foci found within the prostates of men 
around the world regardless of diet, occupation, lifestyle, or other factors. 
Essentially all men with circulating androgens will develop microscopic prostate 
cancer if they live long enough (Bostwick, 2004)”. Prostate cancer grows slowly 
and usually becomes constricted to the prostate gland where it might not be 
harmful. Some types of prostate cancer may require no treatment, while other 
types can aggressively spread. In the early prostate cancer stages, cancer may 
not necessarily cause symptoms or signs. In contrast, advanced-stage prostate 
cancer might cause symptoms. For instance, it may cause urination difficulties, 
bloody semen, and painful pelvic region, erection dysfunctions. In most of the 
cases, prostate cancer is detected incidentally; during routine yearly Digital 
Rectal Exam (DRE) performed by the urologist. During a DRE, the physician 
uses lubricated gloves to cover his finger and he/she inserts the finger into the 
patient’s rectum to palpate the prostate gland. If any abnormalities in the prostate 
gland are detected, the patient might need further tests. Also, prostate cancer 
can be detected by a Prostate-specific antigen (PSA) test. In PSA test, the 
physician draws a sample of blood from a vein to check natural substance, which 
is produced by the patient’s prostate gland (Hoffman, 2016). However, these 
tests do not determine the extent and the stages of this cancer. For this reason, 
doctors who think that cancer has spread beyond prostate request advanced 
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imaging exams such as CT and MRI. 
2.3 Prostate Cancer Treatment Options 
 
The prostate cancer treatment depends on some factors. The first factor is how 
fast the prostate cancer grows, the second one is how much cancer has spread, 
and the last factor is the benefits and the complications of the prostate cancer 
treatment. For early-stage prostate cancers, instant treatment might not be 
necessary. Otherwise, physicians recommend: 
2.3.1 Prostate Cancer Active Surveillance 
 
For active-surveillance patients, blood tests (follow-up tests), DRE and prostate 
biopsies might be needed to check the prostate gland cancer progression. If the 
tests demonstrated any cancer progressions, the patient might undergo a 
treatment such as surgery or radiotherapy. The active surveillance can be an 
available option for those who have prostate cancer with no expected-growing 
symptoms (Johnson, 2014). 
2.3.2 Radiation Therapy 
 
There are two ways to deliver the prostate cancer radiation therapy. The first way 
is using external beam radiation in which high-energy X-rays are sent to the 
prostate cancer to kill the cancerous cells. The second way is the radiation 
brachytherapy, which involves inserting some radioactive seeds into the prostate 
gland. The seeds deliver radiation with small dose over an extended period, and 
they are implanted into the prostate using a needle for guidance by ultrasound 
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images (Greenfield, 2011).  
2.3.3 Prostate Cancer Surgery 
 
The prostate gland cancer can be removed by three different ways. First, through 
making an incision in the patient’s lower abdomen and this surgery may cause 
nerve damage leading to bladder health issues as well as erection difficulties. 
Second, through making a surgical opening between the patient’s scrotum and 
anus. This surgery may allow for faster recovery, but it can be more difficult for 
doctors to avoid the nerves while removing the surrounding lymph (Comploj, 
2012). Lastly, laparoscopic radical prostatectomy and it can be done through a 
small incision in the patient’s abdomen and a laparoscope is used (small tracking 
camera). This surgery may carry risks to the nearby structures. For this reason, it 
is not commonly requested for prostate cancer treatment (Finkelstein, 2010). 
2.4 Prostate Cancer Imaging 
2.4.1 The Role of Trans-rectal Ultrasound (TRUS) 
 
TRUS is a common clinical imaging technique used in clinical sites. It is 
important for prostatic cancer biopsy. In case the prostate gland cancer is 
suspected, the proper diagnostic exam is the biopsy in conjunction with US. Prior 
to biopsy, the patient is injected with an enema to clean up the rectum. 
Afterwards, TRUS probe is inserted in the patient’s rectum. After visualizing the 
prostate and seminal vesicles, the US images are obtained in axial and sagittal 
views. Then, a needle guide is used to perform prostatic biopsy, which help 
doctors to make the pathologic interpretation (Hricak, 2007). 
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2.4.2 The Role of CT Scan 
 
Since the soft tissue contrast of CT is so low, sometimes it is hard to visualize the 
intra-prostatic and peri-prostatic structure. However, the major role of CT is in the 
prostate cancer staging. In some cases, CT visualizing ability is limited. If the 
patient’s PSA level is > 20 ng/mL, his Gleason score is > 7, and the clinical tumor 
stage is 3 or higher, CT should be considered (Hricak, 2007). 
2.4.3 The Role of MRI 
 
2.4.3.1 T2-Weighted Imaging 
 
T2W imaging is mainly used to visualize anatomy and to assess the seminal 
vesicles and the prostate capsule. Also, It is used to assess the prostate cancer 
stage. T2W imaging has a high spatial resolution, superior soft tissue contrast, 
and a large FOV. On T2W imaging, the tumor appears hypo-intense in the 
peripheral zone while the normal peripheral zone appears hyper-intense. For this 
reason, the tumor is easily identified. However, changes of signal intensity on 
T2W images within the prostate region must be interpreted carefully. Some other 
pathologies may appear similar to cancer on T2W images. After the prostate 
cancer biopsy is done, it is highly recommended to wait 8–12 weeks to perform 
T2W-MRI exam. This way the image misinterpretation can be avoided (Gillian 
Murphy, 2013). 
2.4.3.2 Dynamic Contrast Enhanced T1-W MRI (DCE MRI) 
 
The angiogenesis and vessels permeability in cancerous cells make DCE-MRI 
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the best technique of choice for imaging cancerous tissues. DCE-MRI provides a 
high quality visualization of prostatic-tumor vascularity. Also, using DCE-MRI 
allows visualizing tissue perfusion and cellular leakage. In DCE-MRI of prostate, 
a series of fast gradient-echo T1W images are acquired immediately prior, 
during, and after gadolinium-based contrast injection. This is because the onset 
time to enhancement, time to enhancement peak, during the enhancement peak, 
and washout time of DCE-MRI can differentiate cancerous tissues from normal 
tissues (Murphy, 2013). 
2.5 CT Versus MRI In Prostate Treatment Planning 
 
 CT and MRI contoured prostate gland volumes were compared and significant 
differences between both volumes were shown. The CT-contoured prostate 
volume was 2-7 mm larger than the MRI-contoured prostate volume (See figure 
6). The MRI contoured volume was superior to CT regarding the visualization of 
the prostate apex (Tiina Seppälä, 2015). Also, it has been confirmed that MRI 
contouring enables radiation dose reduction to the rectum during the prostate 
treatment. The rectum volume received 80% of the prescribed dose when MRI-
based volumes were used compared to CT volumes (Debois, 2013).“The 
average dose delivered to the rectum might be reduced from 74.9% to 64.2% of 
the prescribed dose by applying MRI contouring instead of CT contouring of the 
prostate. For this reason, MRI-based volumes were more accurate than CT in 
terms of precise delineation of the prostate and its surrounding structures and 
organs (Buch, 2015)”. 
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Figure 6: Prostate contours and related surrounding structures on CT (left image) and 
MRI (right image). In orange is prostate, in red is right neurovascular bundle, in yellow is 
left neurovascular bundle, and in green is the rectum (Bush, 2013). 
 
2.6 The CyberKnifeTM  Prostate Stereotactic Body Radiation Therapy 
 
Radiation therapy scan can be performed using some technologies such as 
Intensity-Modulated Radiation Therapy (IMRT) or 3D-Conformal Radiation 
Therapy (CRT). Over the years, newer and more precise methods such as the 
CyberKnifeTM or linear accelerator (LINAC) have been developed and are used 
routinely in specialized centers. The CyberKnifeTM developed in the 1990s, and it 
is known as a Stereotactic Body Radiation Therapy (SBRT) system, which is 
made to perform very precise radiosurgeries in different areas in the human body 
(Katz, 2010). The CyberKnifeTM SBRT system is able to produce three-
dimensional tumor localization and release multiple direction radiation beams for 
the purpose of destroying the tumor (See figure 7). The CyberKnifeTM SBRT 
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allows the delivery of very high-radiation dose with high precision to the target 
with negligible damage to the healthy tissues surrounding the targeted organ. 
The CyberKnifeTM has proven its effectiveness as an alternative technique that 
can be used for treating small tumors. A high performance linear accelerator 
combined with a robotic arm makes treatment more precise. The standard linear 
accelerator has only a single rotational movement in one plane. The robotic arm 
in the CyberKnifeTM has six degrees of moving freedom. Because the radiation 
treatment beams in the CyberKnifeTM can be directed from various angles, the 
CyberknifeTM can be called the non iso-centeric radiation therapeutic modality 
(Gopalakrishna, 2010). The CyberKnifeTM system has sub-millimeter accuracy, 
which is suitable for treating respiration-related movement targets and central 
nervous system targets. Since the prostate gland constantly moves during the 
delivery of radiation therapy, the CyberknifeTM treatment system accounts for 
those movements during the treatment. Considerable intra-fractional prostatic 
motion was recorded with a range up to 3 mm, 6 mm and 8 mm in both vertical 
and horizontal directions, roughly (Siyuan Lei, 2011). Also, it was reported that 
intra-fractional prostatic motion could be similar or greater than 1 cm over a 
period of 8 minutes (Armas, 2015). The superior advantage of the CyberKnifeTM 
system is that it requires no anesthesia and patients can resume daily-life 
activities immediately after the fractionated treatment. Also, it has been invented 
to minimize the geometrical limitations of conventional treatment modalities and 
to reduce the invasive doses of SBRT systems (Katz, 2013). 
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Figure 7: The CyberKnifeTM room (UCSF, 2016). 
 
6.2.1 The CyberKnifeTM System 
 
The CyberKnifeTM system is composed of two diagnostic X-ray sources and 
digital X-ray detectors. A constant update of the patient’s and target position is 
provided. This system permits the robotic arm to compensate for any minor 
changes in patient position at the same time of treatment delivery. A flexible 
positioning table allows an automatic patient re-positioning before and during 
beam delivery. The CyberKnifeTM system contains some very sensitive optical 
tracking sensors that are used for tumor movement compensation, which may 
result from respiration during treatment delivery. Planning and procedure 
monitoring screens are located outside the CyberKnifeTM shielded room to assist 
radiotherapists monitoring the patients during the hypo-fractionated treatment 
(Smith, 2007) (See figure 8). 
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Figure 8: The CyberKnifeTM technical components (Smith, 2007). 
2.6.2 The CyberKnifeTM Prostate SBRT Treatment Workflow 
 
The CyberKnifeTM-based prostate SBRT is carried out by a multidisciplinary 
clinical team involving a radiologist, a radiation oncologist, a medical physicist 
and a radiation therapist. Before the radiotherapy treatment begins, the workflow 
starts with the first step, which is the patient preparation. At least one week prior 
to acquiring the CT scan for SBRT treatment planning, radiopaque fiducial 
markers are implanted by an ultrasound trans-rectal special exam to place the 
markers inside the prostate gland. Then at the CT scan for treatment planning, 
the patient is placed in a customized cast body support for immobilizing him on 
the treatment table. Additional imaging scans of MRI are also acquired for better 
visualization of soft tissue organs including prostate, intra-prostatic lesions, 
urethra, penile bulb, and neurovascular bundles. These imaging examinations 
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are employed as inputs for contouring both the volumes of disease (GTV and 
CTV) and the sensitive normal tissues close to the target volumes. In the normal 
workflow, the oncologist and radiologist work closely to delineate GTV and CTV, 
as well as the surrounding organs at risk (OARs) as mentioned. Next, plan 
optimization is carried out to achieve the clinical treatment goal of adequate 
target volume coverage by prescription dose, and at the same time making sure 
that the radiation dose to the surrounding organs at risk are all within tolerance 
based on prostate SBRT dosimetry guidelines (such as RTOG 0938) for OAR 
dose-volume constraints. The optimization process will select and optimize the 
number, orientation and MU (monitor unit) of beams for treatment. Upon 
completion of the treatment plan optimization, radiation oncologist will review and 
approve the plan for treatment, and the plan will then go through a quality 
assurance (QA) check by a second physicist and peer review at chart round 
before delivering the treatment. During the treatment, the patient remains 
immobilized to minimize movements while keeping the patient in a comfortable 
position. Next, real-time X-ray projections are required to determine the prostate 
position and orientation, which are compared to the planned prostate position 
and orientation. Any detected deviations in the real time data from plan are 
corrected before (if larger than a set of pre-selected tolerance) or during beam 
delivery. After computing the data the system can approximately align the 
patient’s real position with the planned position. The system continues 
maneuvering until a certain alignment threshold is met. Finally, accurate 
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alignment is then accomplished by using the robotic manipulator. The robotic arm 
moves around the patient and treatment beam delivery can begin in a continuous 
manner. The CyberKnifeTM beam gantry follows a certain path around the patient 
as optimized by the treatment plan. During treatment delivery, the imaging 
system makes frequent check for the patient’s alignment and calculates the 
prostate position. Prostate displacement information is used to allow the robotic 
arm to automatically modify its delivery and compensate for prostate movement. 
However, when the prostate movement level is minimized, the operator can 
control the imaging frequency reduction for the sake of expediting the treatment. 
Also, when the prostate motion exceeds an acceptable displacement limit, the 
beam delivery is stopped and the prostate can be re-aligned. The same workflow 
can be repeated by the clinical team for any radio-therapeutic treatments that 
require more than one fraction. 
2.6.3 Subsystem As Used in the CyberKnifeTM Prostate SBRT Treatment 
 
All Individual elements, which the CyberKnifeTM radiotherapy systems rely on, are 
described and how they contribute to enhance the clinical workflow. Accuray (the 
vendor) has equipped the CyberKnifeTM system with software known as the 
Accuray CyberKnifeTM MultiPlan. This software enables clinical teams to achieve 
the step of visualizing and contouring anatomical structures in an accurate 
manner. These essential procedures may be done remotely from clinicians 
practice office or hospitals via computer network connections and it can increase 
clinical efficiency. A series of medical images (CT, MRI) is imported to the 
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CyberKnifeTM Multiplan software. The multi-modality image fusion methods are 
incorporated into the treatment planning system to enable the optimal use of the 
possibility of different imaging modality. Sophisticated-built in drawing tools allow 
the clinical team to contour the target and other related anatomical regions on 
any of the fused images, giving the required number of structures for dose 
planning. 3D visualization features make an efficient viewing of anatomical 
regions and proper dose calculation of the target volume and neighboring healthy 
tissues.  
Chapter III: Methods and Materials 
3.1 Patient Selection and Preparation 
 
A number of 3 prostatic cancer patients were scanned in the treatment position 
with both MRI and CT. Four fudicial markers were implanted into the prostate. 
The actual RT was planned and delivered according to the current CT-based 
clinical protocol, and based on target volumes drawn by the physician 
responsible for treatment of the patients. Two days prior to the CyberKinfeTM 
treatment planning, patients were asked to follow the low residual and low gas 
diet to remove the amount of gas produced in the bowls. Also, they were asked 
to eat light dinner prior to 5:00 pm the night before the scans. At 5:00 pm the 
night before the scans, then they had to take 2 Dulcolax (Bisacodyl) 5 mg tablets 
by mouth and they also had to take 2 Gas-X (Simethicone) 80 mg tablets to 
decrease gas production. During the day of the treatment planning scans, the 
patients were asked to take 1 fleet Enema 2 hours prior to their appointment 
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time.  
3.2 MRI and CT Scans 
 
MRI was performed using a 1.5T MRI scanner Philips Achieva. The prostate 
patient imaging included non-contrast T2-weighted (coronal, axial views) images 
and BLISS (axial view) images for the diagnostics of prostate (Philips Healthcare; 
matrix 200 X 200; field of view, 200 X 200mm; slice thickness 3mm, XL Torso 
coil placed over a flat board for immobilization purposes. The images covered the 
whole penile bulb and seminal vesicle. All markers were visible in BLISS images 
as hyper-intense dots and their location was confirmed. CT scan images were 
obtained using the CT scanner (Philips Healthcare, CT Brilliance Big Bore). The 
imaging volume (slice thickness 1.5 mm, matrix 512 X 512, FOV 500 mm, 120 
KV, 50 MA) covered the area of the T2 and BLISS images. The filling state of the 
bladder and rectum were controlled with written instructions. All patients emptied 
their rectum with 1 (Fleet Enema) 2 hours before imaging. Also, they were guided 
to empty their bladder and then drink two glasses of water 1 h before the first 
imaging procedure. During the exams, they were lying in a supine RT treatment 
position on a rigid flat and indexed table top, immobilized using the Securevac 
cushion (Bionix) for both MRI and CT, which were carried out on the same day. 
3.3 The CyberKnifeTM Prostate Treatment Planning 
3.3.1 MRI/CT Image Fusion 
Rigid co-registration of the CT and T2W-MRI images was performed using the 
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RT image processing software, which is equipped with a high-quality monitor 
(MIM 5.4, MIM Software Inc., Cleveland, OH, USA). The CT and the T2W-MRI 
images were fused based on the middle point of the fudical markers. The 
prostatic borders and capsule were compared in three views, to confirm precise 
anatomical alignments. The T2W-MRI sequence gives optimal visualization of 
the urethra and prostate; the BLISS-MRI sequence helps identifying the fiducial 
markers, which provide a low signal in the T2-W-MRI images. Minor adjustments 
of co-registration were made if the borders of the prostate in both images did not 
become superimposed. Overlapping issues can be due to possible marker 
displacements. The angle rotation and the image co-registration, as well as the 
displacement of the central point of the fiducial markers in both images were 
accurately measured.  
3.3.2 The CyberKnifeTM Prostate SBRT Contouring and Planning 
 
A radiologist and a radiation oncologist and both are first-hand experienced and 
specialized in prostate. They delineated the prostate capsule in CT and T2W-
MRI images in an independent way. The images were drawn randomly and 
separately. At this stage, the MRI and CT images were not fused. The prostate 
and radiosensitive structures in CT and MRI were defined by the radiation 
oncologist and the radiologist (See figure 8). 
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Figure 8: Three plane CT images (at the top) and three plane MRI images (at the 
bottom) after drawing and before registration. OARs including prostate are delineated. 
Red=prostate, green=rectum, light red within the prostate=urethra, pink=femoral heads, 
orange=bladder, yellow under prostate=LT NVB, purple=RT NVB (BMC, 2016). 
 
The oncologist set up the volumetric center of the delineated prostate based on 
the iso-center of the plan. The anterior, posterior, right, and left directions were 
planned based on the prostate chestnut shape and dimensions in order to give 
geometrical variations. Those variation of the prostate contours had to be 
towards both the balder and rectum. Based on RTOG 0938 protocols, the GTV 
(Gross Tumor Volume) was prescribed by the physician along with the CT and 
MR clinical planning information. The GTV based on the protocol was the 
prostate only. The CTV (Clinical Target Volume) was as the same as the GTV; 
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however, it included only the prostate without including the seminal vesicles as 
described in a routine-axial CT scan. The PTV (Planning Target Volume) was 
defined exactly as the CTV plus a margin of 3 mm posteriorly and a margin of 5 
mm in all other dimensions. For the purpose of meeting, meet RTOG0938 dose 
constraints and requirements, the anterior margin had to be reduced to 3 mm. 
For all cases, the prescription iso-dose line successfully encompassed a 
minimum of 95% of the PTV. For the CyberKnifeTM patients, the maximum dose 
permitted within the PTV was 20% over the prescribed dose. Efforts were done 
to keep the maximum dose within the PTV close to the maximum dose for 
(IMRT) and proton treatments. The prescribed doses of the required arm of this 
study were inside of the PTV. Planning hotspots were adjusted to avoid the 
prostatic-rectal and prostatic-bladder anatomical regions. The prostate treatment 
planning was performed using the Accuray CyberKinfeTM Multiplan treatment 
planning system (Sunnyvale, CA, USA). The normal tissues contoured in this 
study were bladder, rectum, both femoral heads (at the ischial tubercles level), 
seminal vesicles, penile bulb, skin, neurovascular bundles and urethra. For the 
CyberKnifeTM treatment, the visualization of the urethra was required with a 
maximum point dose of 0.03 cc, which exceeded 38.78 Gy (5 fractionated arm). 
All contoured organs were planned on both CT and MRI except urethra and 
neurovascular bundles (more clear in MR volumes than CT volumes). The 
bladder had to be contoured from the base to its apex. Also, the rectum had to be 
contoured from the anus (at the ischial tubercles level) for a length of 15 cm. All 
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tissues within or surround the skin and PTVs were labeled as undetermined 
tissues. The treatment delivery doses that did not follow these given limits were 
constituted as a variation acceptable or deviation unacceptable protocol violation 
(RTOG0938, 2011). The contours were measured horizontally and vertically. 
Horizontal measures were done in left, right, anterior and posterior directions of 
the prostate. Vertical measures were done in the base and apex of the prostate 
(See figure 9 & 10). 
 
Figure 9: includes the CT volume treatment planning, which was completed through the 
CyberKnifeTM Multiplan system, and it is showing the prostate PTV and other dose 
constraints before the optimization step (BMC, 2016). 
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Figure 10: includes MR volumes treatment planning, which was completed through the 
CyberKinfe treatment system, and it is showing the prostate PTV and all other dose 
constraints before the optimization step (BMC, 2016). 
 
3.3.3 Treatment Planning Optimization and Evaluation 
 
This optimization method enables solving planning problems and optimizes 
multiple treatment planning doses. During the treatment planning, the possibility 
of optimizing the radiation doses is retained or relaxed after each step by 
applying a specific user-defined value. This value can improve the planning 
quality and enable meeting the dose constraints and limits. In this study, the 
implementation of the CyberKnifeTM sequential optimization was achieved in the 
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same day of the target planning. It was run to meet the RTOG 0938 dose 
constraint requirements and to achieve the following clinical goals: First, to cover 
at least 95% of PTV with 100% of the prescription dose (3625 cGy). Second, to 
meet all dose requirements for OARs; 1) It should keep the volume of urethra, 
which received (3878 cGy) 107% of the prescription dose; 2) to minimize the 
volume of rectum received 3806 cGy of the prescription dose below 1 cc, volume 
received 3440 cGy below 3 cc, volume receiving 90%, 80% and 50% of the 
prescription dose below 10%; 3) Bladder volume received 3806 cGy below 1 cc, 
volume receiving 90% and 50% of the prescription dose below 10% and 50%; 4) 
Penile bulb maximum dose below 3625 cGy and volume receiving greater or 
equal to 20 cGy below 3 cc; 5) Left and right femoral heads, volume receiving 20 
cGy below 10 cc. 6) Skin: no area of skin receiving dose above 3000 cGy. 
Finally, to obtain a high conformal dose distribution (conformity index below 1.2 
or below 1-2-1.5) around the target with no hot spots over 107% beyond 
prescription dose in normal tissue. After having an acceptable quality plan, the 
beam reduction tools were used to make the best compromise between 
treatment efficiency and dosimetric quality (See figure 11). 
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Figure 11: includes the both CT an MR volumes after the step of fusion and contouring, 
the DVH histogram at the right top corner shows the estimated dose spread for all 
included organs and at this optimization step, medical physicist can manipulate the max 
dose and the beam to meet the RTOG 0938 criteria (BMC, 2016). 
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Chapter IV: Result 
4.1 Prostate Doses 
 
Based on the RTOG 0938 guideline for the CyberKnifeTM prostate SBRT 
planning, this study has shown that comparable prostate dose coverage can be 
achieved for both CT-based volumes and MRI-based volumes, that is to have at 
least 95% of the PTV covered by the prescription dose of 725x5 (3625 cGy).  
The minimum dose received by the ent The minimum dose received by the entire 
PTV was between 31.0 Gy and 34.0 Gy) for both CT and MR based plans. The 
maximum point doses were all within 120-125% of the prescription dose. The 
volumes of PTV receiving 4350 cGy or higher were all approximately meeting the 
requirement of the RTOG 0938.  
4.2 Rectum Dose-Volume Profile Comparison 
 
For rectum volumes that receive 3806 cGy (105% of the prescription dose) were 
all below 1.0 cc for both CT-based and MR-based plans, rectum volumes that 
receive 3440 cGy (95% of the prescription dose) were all in the order of 3.0 cc, 
all approximately meeting the RTOG 0938 requirements (2011).  
For MR-based plans, volume of rectum receiving 3263 cGy (90% of the 
prescription dose) were between 96.4% and 97.5%, volume of rectum receiving 
2900 cGy (80% of the prescription dose) were between 92.3% and 94.5%, 
volume of rectum receiving 1813 cGy (50% of the prescription dose) were 
between 75.3% and 88.0%.  
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For CT-based plans, volume of rectum receiving 3263 cGy (90% of the 
prescription dose) were between 90.4% and 91.6%, volume of rectum receiving 
2900 cGy (80% of the prescription dose) were between 83.1% and 85.3%, 
volume of rectum receiving 1813 cGy (50% of the prescription dose) were 
between 64.9% and 66.4%.  
4.3 NVBs Doses 
The doses delivered to the right and left neurovascular bundles were recorded on 
the MRI-based volumes but not on the CT-based volumes. In MRI, The 
maximum dose to the NVBs wwere between 41590 cGy to 4420 cGy for the MR 
based plans. 
 27 
Table1: CT-based volumes values and dose constraints based on RTOG 0938. 
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Table 2: MRI-based volumes and dose constraints based on RTOG0938. 
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Chapter V: Discussion 
5.1 Inter-modality Differences and Organs at Risk Doses 
 
This study has investigated the systemic doses of prostate and some of the other 
surrounding healthy tissues; specifically, the rectum and NVBs, which may be 
highly affected during the CyberKnifeTM prostate SBRT treatment. Based on the 
data collected at Boston Medical Center, the prostate doses in CT and MRI 
volumes are meeting the RTOG0938 dose constraints, however, the MRI 
prostate dose was much smaller and accurate than the CT prostate dose. To 
illustrate that, the minimum dose received by 95% of the prostate PTV must be 
above 95%. Therefore, the MRI minimum dose received by 95 % of the prostate 
was 95.6% unlike CT minimum dose, which was around 95.4%. Regarding the 
rectum dose delivery, the MR-based volumes well met the RTOG0938 protocol 
requirements comparing to the CT-based volumes. In other words, 90%, 80% 
and 50% of the prescription doses in the rectum CT-based volumes were larger 
than the same prescription doses in the rectum MRI-based volumes, which make 
the MRI modality more accurate than the CT modality. For the bladder doses, 
MRI modality volumes met the dose requirements and constraints and the CT 
volumes did not meet at some points. However, the bladder MRI-based volume 
doses were smaller than the bladder CT-based volumes. The average maximum 
point dose in CT volumes exceeded 1 cc, which means that the patient will be 
exposed to unnecessary treatment doses. Also, the bladder CT-based volumes 
met the required prescription doses and the bladder MRI-based volumes 
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sufficiently met the required prescription doses. This means that MRI is still 
superior to CT in terms of rectum doses delivery. The penile bulb dose in both 
CT and MRI- based volumes were less than 3 cc (RTOG0938 protocol). 
However, the penile bulb dose based on the MRI volume was much smaller than 
the CT volumes, and this shows that the MRI soft tissue superiority over CT. In 
skin and urethra, both volumes have similar values; however, the urethra dose 
delivery based on the MRI volume perfectly met the requirements and showed 
larger value than 38.78 Gy compared to the urethra CT volumes, which was 37.4 
Gy. Overall, MRI-based volumes are much accurate than CT based volumes 
particularly for the CyberknifeTM prostate SBRT treatment planning. 
5.2 Study Limitations and Future Directions 
 
Since this study primarily focuses on the CyberknifeTM as a radiation therapy 
treatment technique, meeting the RTOG0938 dose constraints was quite 
challenging and the reason is that the CyberknifeTM technique used for treating 
small tumors and reducing the dose shells is hard to medical physicists and 
dosimetrists. In addition, the dataset collected lacks the CT-based contouring of 
NVBs. For this reason, the NVBs dose comparison was not included in this work. 
Further cases and additional modifications needed to answer the other half of the 
study empirical question. 
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Chapter VI: Conclusion 
In conclusion, this study has demonstrated through real patient cases that the 
soft tissue contrast of MRI-based volumes is more accurate for the CyberKnifeTM 
prostate SBRT compared to the CT-based volumes. For CT-based and MR-
based SBRT plans, the PTV dose coverage per RTOG 0938 can be achieved, as 
well as the dose-volume constraints for the rectum volumes. However, a 
preliminary dose-volume profile comparison between the two set of plans 
revealed noticeable differences in DVHs for the rectum, with the CT-based plans 
showing a generally higher DVH than the MR-based plans. This potentially could 
be significant for dose reduction to the rectum for the CyberKnifeTM prostate 
SBRT leading to lower rectum toxicity. In addition, we also recorded dose to the 
NVBs for the MR-based plans, which have not been available for CT-baesd 
plans. In summary, using MRI-only-based volumes for the CyberKnifeTM  prostate 
SBRT can provide higher accuracy treatment of prostate target volumes while 
better preserving normal tissues such as rectum. 
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